References
- Cancer Statistics Review 1975-2007: Introduction. US: Surveillance Epidemiology and End Results (2010). [cited 2010 June 20]. Available from: http://seer.cancer.gov/csr/1975_2007/results_figure/sect_01_intro1_7pgs.pdf
- Cibas ES (2010). Fine-needle aspiration in the work-up of thyroid nodules. Otolaryngol Clin N Am, 43, 257-71. https://doi.org/10.1016/j.otc.2010.01.003
- Enewold L, Zhu K, Ron E, et al (2009). Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev, 18, 784-91. https://doi.org/10.1158/1055-9965.EPI-08-0960
- Eszlinger M, Paschke R (2010). Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. Molecular and Cellular Endocrinology, 1, 1-9.
- Guan H, Ji M, Bao R, et al (2009). Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab, 94, 1612-7. https://doi.org/10.1210/jc.2008-2390
- Handkiewicz-Junak D, Czarniecka A, Jarzab B (2010). Molecular prognostic markers in papillary and follicular thyroid cancer: current status and future directions. Mol Cell Endocrinol, 1, 1-21.
- Hayashida N, Namba H, Kumagai A, et al (2004). A rapid and simple detection method for the BRAFT1799A mutation in fine-needle aspirated thyroid carcinoma cells. Thyroid, 14, 910-5. https://doi.org/10.1089/thy.2004.14.910
- Howell GM, Nikiforova MN, Carty SE, et al (2012). BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol, 10, 2611.
- Kato MA, Fahey TJ (2009). Molecular markers in thyroid cancer diagnostics. Surg Clin N Am, 89, 1139-55. https://doi.org/10.1016/j.suc.2009.06.012
- Kebebew E, Weng J, Bauer J, et al (2007). The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg, 246, 466-71. https://doi.org/10.1097/SLA.0b013e318148563d
- Kim SW, Lee JI, Kim JW, et al (2010). BRAFV600E mutation analysis in fine-needle apiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population. J Clin Endocrinol Metab, 95, 3793-800.
- Knauf JA, Ma X, Smith EP (2005). Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res, 65, 4238-45. https://doi.org/10.1158/0008-5472.CAN-05-0047
- Li C, Lee KC, Schneider EB, et al (2012). BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab, 97.
- Nikiforov YE (2008). Thyroid carcinoma: molecular pathways and therapeutic targets. Modern Pathol, 21, 38-43.
- Nikiforov YE, Steward DL, Robinson-Smith TM, et al (2009). Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab, 94, 2092-8. https://doi.org/10.1210/jc.2009-0247
- Nikiforova MN, Nikiforov YE (2009). Molecular diagnostics and predictors in thyroid cancer. Thyroid, 19, 1361-61.
- Sapio MR, Guerra A, Posca D, et al (2007). Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fineneedle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocrine-Related Cancer, 14, 1089-97. https://doi.org/10.1677/ERC-07-0147
- So KY, Son Y, Park JY, et al (2011). Preoperative BRAF mutation has different predictive values for lymph node metastasis according to tumor size. Otolaryngol Head Neck Surg, 145, 422-27. https://doi.org/10.1177/0194599811404649
- Tee YY, Lowe AJ, Brand CA, Judson RT (2007). Fine-needle aspiration may miss a third of all malignancy in palpable thyroid nodules. Ann Surg, 246, 714-20. https://doi.org/10.1097/SLA.0b013e3180f61adc
- Tjindarbumi D, Mangunkusumo R (2002). Cancer in Indonesia, present and future. Jpn J Clin Oncol, 33, 17-21.
- Wartofsky L (2010). Increasing world incidence of thyroid cancer: increased detection or higher radiation exposure? Hormones, 9, 103-8. https://doi.org/10.14310/horm.2002.1260
- Xing M (2007). BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocrine Reviews, 29, 742-62.
- Xing M (2009). Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endrocinol, 10, 1-8.
- Xing M, Tufano RP, Tufaro AP, et al (2004). Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab, 89, 2867-72. https://doi.org/10.1210/jc.2003-032050
- Xing M, Westra WH, Tufano RP et al (2005). BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab, 90, 6383-9.
- Xing M, Clark D, Guan H, et al (2009). BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol, 28, 3077-82.
- Yip L, Nikiforova MN, Carty SE, et al (2009). Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery, 146, 1215-23. https://doi.org/10.1016/j.surg.2009.09.011
- Zatelli MC, Trasforini G, Leoni S, et al (2009). BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinology, 161, 467-73. https://doi.org/10.1530/EJE-09-0353
Cited by
- Elevated Expression of Nuclear Protein Kinase CK2α as a Poor Prognosis Indicator in Lymph Node Cancerous Metastases of Human Thyroid Cancers vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7425
- Associations of the BRAF (V600E) mutation and p53 protein expression with clinicopathological features of papillary thyroid carcinomas patients pp.1792-1082, 2015, https://doi.org/10.3892/ol.2015.3401
- Clinical impact of BRAF mutation on the diagnosis and prognosis of papillary thyroid carcinoma: a systematic review and meta-analysis vol.46, pp.2, 2016, https://doi.org/10.1111/eci.12577